Dr. Choosak obtained his medical degree from Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok in 1983 and went on to complete a Diploma in Clinical Science and a Certificate of Proficiency in Urologic Surgery from Ramathibodi Hospital in 1987. He has been a lecturer and staff member at the Department of Surgery, Faculty of Medicine, Prince of Songkla University since 1987. With special interest in genitourinary tract tumor, he has served as a superintendent of several research projects in genitourinary tract tumor of Prince Songkla University and Thai Urological Association. He actively supports and facilitates the training and networking of comprehensive care for malignancy of genitourinary tract among Thai urologists. Over this past few years, as a pioneer experiencing treatment of mCRPC in the country, he and his department participate in a number of clinical trials as a principle investigator. In 2013, he was appointed to be chairman in intensive course training in prostate cancer management and be an editor for a textbook for Thai urologist to use as a reference. He was also one of the guidelines committee in prostate cancer treatment in Thailand. A member of the Royal College of Surgeons of Thailand, he has been on the Executive Committee of the Thai Urological Association (TUA) (in Royal Patronage) since 2003. In May 2015, he became President of the TUA, a post he is due to hold for 2 years.
Dr. Evans is professor and chairman of the Department of Urology at University of California, Davis School of Medicine and a member of the UC Davis Cancer Center. Dr. Evans attended Dartmouth Medical School on a Health Professional Services Program scholarship and he served on active duty in the United States Army, including two years as Chief of Experimental Surgery at the Walter Reed Army Institute of Research. He completed surgery and urology training at the University of California, San Francisco where he was also a National Kidney Foundation Scholar. Dr. Evans completed fellowship training in urologic oncology at the University of Texas, M.D. Anderson Cancer Center. He came to UC Davis in 1997 at which time he was also Director of Urology Research. In 2006, Dr. Evans became Department Chairman, and in 2010 he became Chairman of the UC Davis Medical Group Practice Management Board. Dr. Evans’ practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy.
Dr. Evans’ research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor. His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.
Dr. Evans is president-elect of the Society of Urologic Oncology and is Immediate Past Chair of the ASCO-GU Steering Committee. He is also an elected member of the American Association of Genitourinary Surgeons. His research laboratory has received funding from the National Institutes of Health, Department Of Defense, New York Academy of Medicine, Prostate Cancer Foundation, Stand-Up To Cancer and the American Cancer Society. He has published over 140 peer-reviewed articles.
Christopher Reginald Chapple
Christopher Reginald Chapple
Christopher Chapple is a Consultant Urological Surgeon at Sheffield Teaching Hospitals, Honorary Professor at University of Sheffield and Visiting Professor at Sheffield Hallam University. He has a particular interest in functional reconstruction of the lower urinary tract and the underlying pharmacological control mechanisms, and provides a tertiary service in lower urinary tract reconstructive surgery. He trained at the Middlesex Hospital where he completed his doctorate thesis. He continued there and the Institute of Urology in London for his sub-specialist training. He is Secretary General of the European Association of Urology, having previously been Chairman of the International Relations Committee, Adjunct Secretary General Responsible for Education, and Director of the European School of Urology. He was editor-in-chief of the journal Neurourology and Urodynamics from 2006-2016 and is on the editorial board of several international journals. He is an active member of many urological associations and societies including the British Association of Urological Surgeons, the European Association of Urology, the International Continence Society, the Association of Academic European Urologists and the American Association of Genitourinary Surgeons. He has chaired a number of guidelines initiatives including the NICE Guidelines Development Group on male LUTS and was co-chairman of the ICUD consultation on male LUTS. BAUS awarded him the St Peter’s medal 2011 and SUFU awarded him the Lifetime Achievement Award in 2015. Prof. Chapple has co-authored 700+ articles, comments and letters in peer-reviewed journals and has written several chapters and books.
Dr. Roger R. Dmochowski is Professor at the Department of Urology at Vanderbilt University in Nashville. He is Director of the Section of Female Pelvic Medicine and supervisor of the Fellowship in Pelvic Medicine at Vanderbilt.He is also Clinical Assistant Professor in Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.
He is also Vice Chair, Section of Surgical Sciences Vanderbilt University Medical Center, Associate Director of Quality and Safety, Vanderbilt Health System,Executive Director of Risk Prevention for Vanderbilt Health System, Executive Medical Director for Patient Safety and Quality (Surgery),Associate Chief of Staff, and Medical Director of Risk Management at Vanderbilt University Hospital.
Dr. Dmochowski received his medical degree from the University of Texas Medical Branch at Galveston. He completed an internship and residency in surgery and urology at the University of Texas Medical School at Houston and at the M.D. Anderson Hospital and Tumor Institute in Texas.In addition, Dr. Dmochowski is subspecialty fellowship trained in female urology, neurourology, urodynamics and reconstructive urology. He is board certified in urology and female pelvic medicine and reconstruction.
Associate Professor Eric Chung is a consultant surgeon at the AndroUrology Centre and has academic appointment in the University of Queensland and Princess Alexandra Hospital.
He is the current chair for the Andrology section in the Urological Society of Australia and New Zealand (USANZ).
As Australia’s leading surgeon expert in the field of urinary and sexual dysfunctions, he has been invited to speak at many national and international meetings, and serves on many national advisory bodies and international organizations.
He runs a wide range of clinical trials and has published extensively in the field of urinary, sexual and reconstructive prosthesis research.
Foo Keong Tatt
Foo Keong Tatt
Prof Foo is currently an Emeritus Consultant and Advisor Department of Urology at the Singapore General Hospital having served as the Head of Department from 1988 to 2001.
He is a Clinical Professor, National University of Singapore, and an Adjunct Professor with Duke-NUS Graduate Medical School. He is in the Board of Examiners for MBBS as well as M Med (Surgery) Degree and member of the Residency Advisory Committee (RAC) for Urology, under the Specialist Accreditation Board, Singapore having served as Chairman (STC Urology) previously.
He was conferred the honorary member of the Malaysian Urological Association in 1999, the Honorary member of the Singapore Medical Association in 2007, Honorary Member Chinese Urological Association in 2010 and Honorary Fellow Sri Lankan Association of Urological Surgeon in 2011. He was given the Wu Jieping Medical Foundation (China) trophy for his contributions to Urology, in 2000. He was accorded the Lifetime Achieving Award by World Chinese Urological Society in May 2008, Carl Storze Life Time Achievement award by the Endourological Society in Dec 2008 and SIU Distinguished Career Award: Societe Internationale d’Urologie in 2009. He was awarded the Distinguished Golden Achievement Award under GCEO Excellence Awards in 2011. He was the Visiting Professor to Peking University in 2000 and, Fudan University Shanghai April 2007. He was the Dr Virendas Desai Visiting Professor 2007, to Muljibhai Patel Urological Hospital, Nadiad Gujarat, India.
He was appointed Honorary Chief Consultant, Xiamen First Hospital, Xiamen, China Oct 2005. He was awarded the Public Administrative Medal (Silver) in 2001 by the President of Singapore. He is the Founder President of the Singapore Urological Association (President 1986 to 1988) and currently member, Board of Trustees for the Association, having served as Chairman previously.
He was the Vice-Chairman for the 5th International Consultation on BPH in Paris, July 2000 and was a member of the Steering Committee for the International Consultation on Urological Diseases (ICUD) (2000 to 2006).
He was the Secretary-General to the Urological Association of Asia from 1998 to 2006, Director of Asian School of Urology from 2006 to 2010 and currently is the Honorary Executive Director of the Urological Association of Asia (UAA) since 2006.
Dr. Masayuki Takeda Professional Training, Teaching Experience, and Employment: 2013-present Dean, University of Yamanashi School of Medicine. 2009-2013 Vice-President, University of Yamanashi Hospital. Vice-Dean, University of Yamanashi School of Medicine. 2003-present Professor & Chairman, Department of Urology, Interdisciplinary School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan 2002-2003 Professor and Chairman, Department of Urology, University of Yamanashi, Faculty of Medicine, Yamanashi 1999-2002 Professor and Chairman, Department of Urology, Yamanashi Medical University, Yamanashi
Michael Stifelman's research parallels his clinical focus and expertise which serves as the under pinnings for his academic productivity. To date, these research activities have led to 87 peer reviewed publications, 10 book chapters and 8 review articles and 62 abstracts presented at national and international meetings. He have also created over 30 educational videos, which have been distributed by the American Urologic Association, European Association Urology and World Congress of Endourology and have been awarded First Prize and Top 10 Videos at these society annual meetings. He recognized early in his career the power of intra and inter departmental and multi-institutional collaboration.
Several years ago, He organized the largest robotic partial nephrectohis consortium in the world that includes John Hopkins, Cleveland Clinic, Washington University and Henry Ford Hospital. Together, we have published seminal papers on outcomes following partial robotic nephrectohis for renal cancer. Over the years, He have developed and helped launch multiple HeRB databases, protocols and multi-institutional projects that have been the source of several important advances in the field His three major areas of research have been the management of kidney cancer, upper urinary tract reconstruction and evaluation of innovative surgical technologies. Some of his major accomplishments have been to develop innovative techniques to minimize warm ischemia during partial nephrectohis and novel robotic surgical techniques for upper urinary tract reconstruction. Within the last 5 years He have pioneered two novel techniques that have been adopted by surgeons worldwide. The first uses near infrared fluorescence (NHeRF) imaging during robotic surgery to minimize trauma to the kidney during partial nephrectohis and confirm adequate perfusion of tissue during reconstructive surgery.
The other utilizes buccal mucosa tissue to replace and repair strictures within the ureter. For this work, we were awarded the title of Best Laparoscopic and Robotic Paper at the World Congress of Endourology Meeting in London. He have conducted numerous retrospective and prospective outcome studies related to management of kidney cancer and upper tract reconstruction that have helped define optimal management of these conditions. He currently have reported the largest single surgeon series on robotic upper urinary tract reconstruction. As a recognized leader in the field of minimally invasive surgery, many companies have engaged me evaluate new technologies designed facilitate minimally invasive surgery.
- Director GU Research Group Paterson Institute Manchester 1997-
- Editorial Board Urological Cancer Abstracts 1998-2002 National Cancer Research Institute (NCRI) Board for Bladder Cancer 2000-4
- National Cancer Research Institute (NCRI) Board for Prostate Cancer 2000-
- Chairman NCRI Prostate Cancer Clinical Studies Group 2003-9
- Editorial Board British Journal of Urology International 2000-8
- Editorial Board Prostate Cancer and Prostatic Diseases 2000-
- Editorial Board Clinical Oncology 2007-
- Editorial Board at Large European Urology 2011-
- MRC Bladder Cancer Trials Meta-Analysis Committee 2001-
- MRC Northern Prostate Collaborative (PromPT) Principal Investigator Manchester arm 2001 –
- Board Member North West Regional NCRN Research Board 2003-9
- Chairman EORTC GU Prostate DOG 2004 –11
- Section Editor for Oncology European Urology 2005/6
- Member CTAAC National Cancer Trial Planning Board 2005-7
- Director MCRC Biobank 2007-NCRN National Advisory Group 2009-
- Vice-Chair EORTC GU Group 2011-14
- International Intermediate Endpoints Panel for Prostate Cancer 2013
- Scientific Consulting Editor BJUI International 2013
- Co-Principal Investigator International Cancer Trials :- STAMPEDE 2005- RADICALS 2006-
- Trial Management Groups PATCH / TRAPEZE / CANTATA 2007-
- National Cancer Information Network Co-Director UK National Centre of Excellence for Prostate Cancer Research 2014-
- Joint Clinical Lead UK National Prostate Cancer Audit 2014-
Neal D. Shore
Neal D. Shore
Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association, currently President-elect. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Current Urology Reports, Chemotherapy Advisor, OncLive, PlosOne and Urology Practice. He has numerous peer reviewed publications and book chapters; he performs peer review for numerous scientific journals.
Education & Training
1981 Graduate from Iwate Medical College, Morioka, Iwate, Japan. 1981-1986 Resident at Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. 1988-1990 Research fellow, Baylor College of Medicine, USA. 1990-1992 Research associate, Baylor College of Medicine, USA. 2002-2004 Associate Professor, Department of Urology, Kitasato University School of Medicine. 2004 to Present, Professor and Chairman, Department of Urology, Jikei University School of Medicine.
2009.8 to present, Visiting Professor, Asian Institute of TeleSurgery, Show Chwan Health Care System, Asian IRCAD-Taiwan.
2009 -2011 Chair, International Committee, Japanese Urological Association. 2010 to 2015, Chair, Scientific Committee, Urological Association of Asia.
2015 to present, Director, Asian School of Urology. 2011 to present, Deputy National Delegate of Societe International d’Urologie.
Professor and Chairman, Jikei University School of Medicine.
Chair, International Committee, Japanese Urological Association. Chairman, Publications Committee of Societe International d’Urologie. Director, Asian School of Urology.
Prostate Cancer. Uro-Oncology
Dr. Soichi Mugiya graduated from Hamamatsu University School of Medicine in 1983. From 2009 to 2012, he served as an Associate Professor of the Department of Urology, Hamamatsu University School of Medicine. Since 2012, he has been a Vice-President, and Director of the Department of Urology and Endoscopic Surgery Center, Suzukake Central Hospital, Hamamatsu, Japan.
He was given the “Olympus Award” at the 22nd Annual Meeting of the Japanese Society of Endourology and ESWL in 2008, which was a topic related to Narrow Band Imaging of the upper urinary tract.His specialty includes Endourology, Urologic Oncology and Urolithiasis. He is an active member of the Japanese Society of Endourology (JSE), JUA and SIU.
Dr. Shingo Yamamoto graduated Faculty of Medicine, Kyoto University in 1981, and started his carrier as an urologist. After training as a resident doctor, he entered Postgraduate School of Medical Science, Kyoto University, and studied and published papers regarding with virulence factors of uropathogenic E. coli. In succession, he continued microbiological research as a visiting scientist at Immunobiology Vaccine Center, University of Alabama at Birmingham, USA for 3 years. After coming back to Japan, he re-started to work as an urologist through Assistant Professor and Associate Professor, Department of Urology, Kyoto University, and Associate professor, Department of Urology, Hyogo College of Medicine. He has been Professor and Chairman, Department of Urology since 2009, and has been Director, Kidney Transplant Center, Hyogo College of Medicine since 2011.
Yukio Homma is Professor and Chair of the Department of Urology at the University of Tokyo. He completed his medical education at The University of Tokyo in 1978. His initial research interest was carcinogenesis and prevention of bladder and prostate cancer.
In late 80s, he started his career specializing in lower urinary tract dysfunctions. His current research interest involves the etiology and assessment of the lower urinary tract dysfunctions including benign prostatic hyperplasia, overactive bladder, and interstitial cystitis. One of his recent achievements is developing overactive bladder symptom score (OABSS), a new symptom assessment tool for OAB. He is an Executive Member of the Japanese Continence Society, and represents for the Japanese Society of Geriatric Urology and the Society of Interstitial Cystitis of Japan. He has published more than 400 English articles in journals of oncology and urology.